Burden of disease attributable to second-hand smoke exposure: A systematic review


Por: Carreras, G, Lugo, A, Gallus, S, Cortini, B, Fernandez, E, Lopez, MJ, Soriano, JB, Lopez-Nicolas, A, Semple, S, Gorini, G, Castellano, Y, Fu, M, Ballbe, M, Amalia, B, Tigova, O, Continente, X, Arechavala, T, Henderson, E, Liu, XQ, Bosetti, C, Davoli, E, Colombo, P, O'Donnell, R, Dobson, R, Clancy, L, Keogan, S, Byrne, H, Behrakis, P, Tzortzi, A, Vardavas, C, Vyzikidou, VK, Bakellas, G, Mattiampa, G, Boffi, R, Ruprecht, A, De Marco, C, Borgini, A, Veronese, C, Bertoldi, M, Tittarelli, A, Verdi, S, Chellini, E, Trapero-Bertran, M, Guerrero, DC, Radu-Loghin, C, Nguyen, D, Starchenko, P, Ancochea, J, Alonso, T, Pastor, MT, Erro, M, Roca, A, Perez, P

Publicada: 1 dic 2019
Resumen:
Our aim was to provide a systematic review of studies on the burden of disease due to second-hand smoke (SHS) exposure, reviewing methods, exposure assessment, diseases causally linked to SHS, health outcomes, and estimates available to date. A literature review of studies on the burden of disease from SHS exposure, available in PubMed and SCOPUS, published 2007-2018 in English language, was carried out following the PRISMA recommendations. Overall, 588 studies were first identified, and 94 were eligible. Seventy-two studies were included in the systematic review. Most of them were based on the comparative risk assessment approach, assessing SHS exposure using mainly surveys on exposure at home/workplaces. Diseases more frequently studied were: lung cancer, ischemic heart disease, stroke, chronic obstructive pulmonary disease, asthma and breast cancer in adults; lower respiratory tract infection, otitis media, asthma, sudden infant death syndrome and low birth weight in children. The SHS exposure assessment and the reported population attributable fractions (PAF) were largely heterogeneous. As an example, the PAF from lung cancer varied between 0.6% and 20.5%. Moreover, PAF were estimated applying relative risks and SHS exposures with no consistent definitions or with different age classes. The research gap on the SHS exposure burden is shrinking. However, estimates are not yet available for a number of countries, particularly the Middle Eastern and African countries, and not all diseases with the strongest evidence of causation, such as sudden infant death syndrome, have been explored. Moreover, in some cases the applied methodology revealed relatively low quality of data.

Filiaciones:
Carreras, G:
 Oncol Network Prevent & Res Inst ISPRO, Via Cosiino Il Vecchio 2, I-50139 Florence, Italy

Lugo, A:
 Ist Ric Farmacol Mario Negri IRCCS IRFMN, Via La Masa 19, I-20156 Milan, Italy

Gallus, S:
 Ist Ric Farmacol Mario Negri IRCCS IRFMN, Via La Masa 19, I-20156 Milan, Italy

Cortini, B:
 Oncol Network Prevent & Res Inst ISPRO, Via Cosiino Il Vecchio 2, I-50139 Florence, Italy

Fernandez, E:
 Catalan Inst Oncol ICO, Granvia LHospitalet 199-203, Lhospitalet De Llobregat 199203, Spain

 Bellvitge Biomed Res Inst IDIBELL, Granvia LHospitalet 199, Lhospitalet De Llobregat 199203, Spain

 Univ Barcelona, Sch Med & Hlth Sci, Dept Clin Sci, Campus Bellvitge,Feixa Lima S-N, Lhospitalet De Llobregat 08907, Spain

Lopez, MJ:
 Publ Hlth Agcy Barcelona ASPB, Pl Lesseps 1, Barcelona 08023, Spain

 CIBERESP, Av Monforte de Lemos 3-5,Pabellon 11,Planta 0, Madrid 28029, Spain

 IIB St Pau, St Antoni Maria Claret 167, Barcelona 08025, Spain

Soriano, JB:
 Hosp Univ La Princesa IISP, 62 1st Floor, Madrid 28006, Spain

Lopez-Nicolas, A:
 Polytech Univ Cartagena UPCT, Plaza Cronista Isidoro Valverde S-N, Cartagena 30202, Spain

Semple, S:
 Univ Stirling, Fac Hlth Sci & Sport, Stirling FK9 4LA, Scotland

Gorini, G:
 Oncol Network Prevent & Res Inst ISPRO, Via Cosiino Il Vecchio 2, I-50139 Florence, Italy

Castellano, Y:
 Bellvitge Biomed Res Inst IDIBELL, Catalan Inst Oncol ICO, Barcelona, Spain

Fu, M:
 Bellvitge Biomed Res Inst IDIBELL, Catalan Inst Oncol ICO, Barcelona, Spain

Ballbe, M:
 Bellvitge Biomed Res Inst IDIBELL, Catalan Inst Oncol ICO, Barcelona, Spain

Amalia, B:
 Bellvitge Biomed Res Inst IDIBELL, Catalan Inst Oncol ICO, Barcelona, Spain

Tigova, O:
 Bellvitge Biomed Res Inst IDIBELL, Catalan Inst Oncol ICO, Barcelona, Spain

Continente, X:
 Publ Hlth Agcy Barcelona ASPB, Pl Lesseps 1, Barcelona 08023, Spain

Arechavala, T:
 Publ Hlth Agcy Barcelona ASPB, Pl Lesseps 1, Barcelona 08023, Spain

Henderson, E:
 Publ Hlth Agcy Barcelona ASPB, Pl Lesseps 1, Barcelona 08023, Spain

Liu, XQ:
 Ist Ric Farmacol Mario Negri IRCCS IRFMN, Via La Masa 19, I-20156 Milan, Italy

Bosetti, C:
 Ist Ric Farmacol Mario Negri IRCCS IRFMN, Via La Masa 19, I-20156 Milan, Italy

Davoli, E:
 Ist Ric Farmacol Mario Negri IRCCS IRFMN, Via La Masa 19, I-20156 Milan, Italy

Colombo, P:
 Gallup Int Assoc, Worldwide Independent Network, Ist DOXA, Milan, Italy

O'Donnell, R:
 Univ Stirling UNISTIR, Stirling, Scotland

Dobson, R:
 Univ Stirling UNISTIR, Stirling, Scotland

Clancy, L:
 TobaccoFree Res Inst Ireland TFRI, Dublin, Ireland

Keogan, S:
 TobaccoFree Res Inst Ireland TFRI, Dublin, Ireland

Byrne, H:
 TobaccoFree Res Inst Ireland TFRI, Dublin, Ireland

Behrakis, P:
 George D Behrakis Res Lab HCS, Hellen Canc Soc, Athens, Greece

Tzortzi, A:
 George D Behrakis Res Lab HCS, Hellen Canc Soc, Athens, Greece

Vardavas, C:
 George D Behrakis Res Lab HCS, Hellen Canc Soc, Athens, Greece

Vyzikidou, VK:
 George D Behrakis Res Lab HCS, Hellen Canc Soc, Athens, Greece

Bakellas, G:
 George D Behrakis Res Lab HCS, Hellen Canc Soc, Athens, Greece

Mattiampa, G:
 George D Behrakis Res Lab HCS, Hellen Canc Soc, Athens, Greece

Boffi, R:
 Fdn IRCCS Ist Natl Tumori INT, Milan, Italy

Ruprecht, A:
 Fdn IRCCS Ist Natl Tumori INT, Milan, Italy

De Marco, C:
 Fdn IRCCS Ist Natl Tumori INT, Milan, Italy

Borgini, A:
 Fdn IRCCS Ist Natl Tumori INT, Milan, Italy

Veronese, C:
 Fdn IRCCS Ist Natl Tumori INT, Milan, Italy

Bertoldi, M:
 Fdn IRCCS Ist Natl Tumori INT, Milan, Italy

Tittarelli, A:
 Fdn IRCCS Ist Natl Tumori INT, Milan, Italy

Verdi, S:
 ISPRO, Florence, Italy

Chellini, E:
 ISPRO, Florence, Italy

Trapero-Bertran, M:
 Polytech Univ Cartagena UPCT, Plaza Cronista Isidoro Valverde S-N, Cartagena 30202, Spain

Guerrero, DC:
 Polytech Univ Cartagena UPCT, Plaza Cronista Isidoro Valverde S-N, Cartagena 30202, Spain

Radu-Loghin, C:
 European Network Smoking & Tobacco Prevent ENSP, Brussels, Belgium

Nguyen, D:
 European Network Smoking & Tobacco Prevent ENSP, Brussels, Belgium

Starchenko, P:
 European Network Smoking & Tobacco Prevent ENSP, Brussels, Belgium

Ancochea, J:
 Hosp Univ La Princesa LISP, Fdn Invest Biomed, Madrid, Spain

Alonso, T:
 Hosp Univ La Princesa LISP, Fdn Invest Biomed, Madrid, Spain

Pastor, MT:
 Hosp Univ La Princesa LISP, Fdn Invest Biomed, Madrid, Spain

Erro, M:
 Hosp Univ La Princesa LISP, Fdn Invest Biomed, Madrid, Spain

Roca, A:
 Hosp Univ La Princesa LISP, Fdn Invest Biomed, Madrid, Spain

Perez, P:
 Hosp Univ La Princesa LISP, Fdn Invest Biomed, Madrid, Spain
ISSN: 00917435
Editorial
ACADEMIC PRESS INC ELSEVIER SCIENCE, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA, Estados Unidos America
Tipo de documento: Review
Volumen: 129 Número:
Páginas:
WOS Id: 000501472300009
ID de PubMed: 31505203
imagen Green Accepted

MÉTRICAS